{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001873","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.158623+00:00","generated_at":"2026-05-28T06:19:08.672982+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M","bullets":["Product revenues, net expected $735M-$750M for 2025.","Jornay PM net revenue expected >$135M in 2025.","Adjusted EBITDA (excl. SBC) expected $435M-$450M.","Adjusted operating expenses (excl. SBC) expected $220M-$230M.","Repurchased $60M in shares in 2024 under $150M buyback program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001873","json":"https://secwatch.observer/filing/0001104659-25-001873.json","markdown":"https://secwatch.observer/filing/0001104659-25-001873.md","text":"https://secwatch.observer/filing/0001104659-25-001873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/0001104659-25-001873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/tm252196d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:19:08.672982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}